Molecular target inhibitors have been regularly approved by Food and Drug Administration
(FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and …

Oncolytic viruses (OVs) represent a new class of multi-modal immunotherapies for cancer,
with OV-elicited antitumor immunity being key to their overall therapeutic efficacy. Currently …

Hyperactivation of PI3K/AKT/mTOR and MAPK/MEK/ERK signaling pathways is commonly
observed in many cancers, including triple-negative breast cancer (TNBC) and melanoma …

Highlights CD40 expression correlates with the type I anti-tumor response and better
survival. Pan-cancer bioinformatics characterization reveals reduced CD40 expression in 11 …

CD40 is a member of the tumor necrosis factor (TNF) receptor superfamily of receptors
expressed on a variety of cell types. The CD40–CD40L interaction gives rise to many …

Targeted therapies, including small molecule inhibitors directed against aberrant kinase
signaling and chromatin regulators, are emerging treatment options for high-grade gliomas …

This review comprehensively explores the challenge of drug resistance in cancer by
focusing on the pivotal PI3K/AKT/mTOR pathway, elucidating its role in oncogenesis and …

Cancer remains a significant challenge in medicine due to its complexity and heterogeneity.
Biomarkers have emerged as vital tools for cancer research and clinical practice, facilitating …

Rigosertib (ON-01910. Na) is a small-molecule member of the novel synthetic benzyl-styryl-
sulfonate family. It is currently in phase III clinical trials for several myelodysplastic …

Background CD40, a TNF receptor family member, is expressed by a variety of immune cells
and is involved in the activation of both adaptive and innate immune responses. Here, we …